Register Now

Anthem Biosciences shares list at 27% premium on bourses

Analysts said that Anthem Biosciences’ IPO was fairly priced, supported by strong growth, industry-leading margins, and steady profitability.

Leave a Reply

Your email address will not be published. Required fields are marked *